Optimizing and Accelerating the Development of Precision Pain Treatments for Chronic Pain: IMMPACT Review and Recommendations.

Pain biomarker neuropathic personalized phenotype precision quantitative sensory testing

Journal

The journal of pain
ISSN: 1528-8447
Titre abrégé: J Pain
Pays: United States
ID NLM: 100898657

Informations de publication

Date de publication:
02 2023
Historique:
received: 11 04 2022
revised: 01 08 2022
accepted: 17 08 2022
pubmed: 6 10 2022
medline: 7 2 2023
entrez: 5 10 2022
Statut: ppublish

Résumé

Large variability in the individual response to even the most-efficacious pain treatments is observed clinically, which has led to calls for a more personalized, tailored approach to treating patients with pain (ie, "precision pain medicine"). Precision pain medicine, currently an aspirational goal, would consist of empirically based algorithms that determine the optimal treatments, or treatment combinations, for specific patients (ie, targeting the right treatment, in the right dose, to the right patient, at the right time). Answering this question of "what works for whom" will certainly improve the clinical care of patients with pain. It may also support the success of novel drug development in pain, making it easier to identify novel treatments that work for certain patients and more accurately identify the magnitude of the treatment effect for those subgroups. Significant preliminary work has been done in this area, and analgesic trials are beginning to utilize precision pain medicine approaches such as stratified allocation on the basis of prespecified patient phenotypes using assessment methodologies such as quantitative sensory testing. Current major challenges within the field include: 1) identifying optimal measurement approaches to assessing patient characteristics that are most robustly and consistently predictive of inter-patient variation in specific analgesic treatment outcomes, 2) designing clinical trials that can identify treatment-by-phenotype interactions, and 3) selecting the most promising therapeutics to be tested in this way. This review surveys the current state of precision pain medicine, with a focus on drug treatments (which have been most-studied in a precision pain medicine context). It further presents a set of evidence-based recommendations for accelerating the application of precision pain methods in chronic pain research. PERSPECTIVE: Given the considerable variability in treatment outcomes for chronic pain, progress in precision pain treatment is critical for the field. An array of phenotypes and mechanisms contribute to chronic pain; this review summarizes current knowledge regarding which treatments are most effective for patients with specific biopsychosocial characteristics.

Identifiants

pubmed: 36198371
pii: S1526-5900(22)00415-1
doi: 10.1016/j.jpain.2022.08.010
pii:
doi:

Substances chimiques

Analgesics 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

204-225

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Robert R Edwards (RR)

Harvard Medical School, Boston, Massachusetts. Electronic address: RREdwards@Partners.org.

Kristin L Schreiber (KL)

Harvard Medical School, Boston, Massachusetts.

Robert H Dworkin (RH)

University of Rochester, Rochester, New York.

Dennis C Turk (DC)

Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington.

Ralf Baron (R)

Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Arnold-Heller-Straße 3, House D, 24105 Kiel, Germany.

Roy Freeman (R)

Harvard Medical School, Boston, Massachusetts.

Troels S Jensen (TS)

Aarhus University, Aarhus, Denmark.

Alban Latremoliere (A)

Johns Hopkins, Baltimore, Maryland.

John D Markman (JD)

University of Rochester, Rochester, New York.

Andrew S C Rice (ASC)

Imperial College, London, UK.

Michael Rowbotham (M)

UCSF, San Francisco, California.

Roland Staud (R)

University of Florida, Gainesville, Florida.

Simon Tate (S)

ICG Life Sciences, London, UK.

Clifford J Woolf (CJ)

Harvard Medical School, Boston, Massachusetts.

Nick A Andrews (NA)

Salk Institute for Biological Studies, San Diego, California.

Daniel B Carr (DB)

Tufts University, Boston, Massachusetts.

Luana Colloca (L)

University of Maryland, Maryland.

Doina Cosma-Roman (D)

Abbvie Pharmaceuticals, Cambridge, Massachusetts.

Penney Cowan (P)

American Chronic Pain Association, Rocklin, California.

Luda Diatchenko (L)

Department of Anesthesia and Faculty of Dentistry, McGill University, Montreal, California.

John Farrar (J)

University of Pennsylvania, Philadelphia, Pennsylvania.

Jennifer S Gewandter (JS)

University of Rochester, Rochester, New York.

Ian Gilron (I)

Queen's University, Kingston ON, Canada.

Robert D Kerns (RD)

Yale University, Departments of Psychiatry, Neurology, and Psychology, New Haven, Connecticut.

Serge Marchand (S)

Universite de Sherbrooke, Quebec, Canada.

Gwendolyn Niebler (G)

Innocoll Biotherapeutics, Princeton, New Jersey.

Kushang V Patel (KV)

Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington.

Lee S Simon (LS)

SDG LLC, Cambridge, Massachusetts.

Tina Tockarshewsky (T)

Ceres Consulting, Poughkeepsie, New York.

Geertrui F Vanhove (GF)

Surrozen Inc., South San Francisco, California.

Daniel Vardeh (D)

Lahey Headache Center, Boston, Massachusetts.

Gary A Walco (GA)

Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington.

Ajay D Wasan (AD)

University of Pittsburgh, Pittsburgh, Pennsylvania.

Ursula Wesselmann (U)

Department of Anesthesiology/Division of Pain Medicine, Neurology and Psychology, The University of Alabama at Birmingham, Birmingham, Alabama.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH